Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.56 |
| ▸ | OGA | O60502 | 5/20 | 0.44 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061183 | 0.90 | MAPKAPK5 (0.59) | MAPKAPK5OGAAKT1FYNPIK3CD | |
| SCHEMBL2060490 | 0.89 | MAPKAPK5 (0.67) | MAPKAPK5OGAFYNPIK3CD | |
| SCHEMBL2060111 | 0.87 | MAPKAPK5 (0.40) | MAPKAPK5OGATTKSYKFYN | |
| SCHEMBL2060336 | 0.84 | MAPKAPK5 (0.61) | MAPKAPK5OGATTKAKT1FYN | |
| SCHEMBL2060183 | 0.82 | MAPKAPK5 (0.61) | MAPKAPK5TTKAKT1FYNPIK3CD | |
| SCHEMBL10160851 | 0.81 | MAPKAPK5 (0.52) | MAPKAPK5OGAAKT1SYKPIK3CD | |
| SCHEMBL1674360 | 0.80 | MAPKAPK5 (0.79) | MAPKAPK5OGASYKFYN | |
| SCHEMBL1674353 | 0.80 | MAPKAPK5 (0.64) | MAPKAPK5OGATTKSYKFYN | |
| SCHEMBL2060198 | 0.79 | MAPKAPK5 (0.57) | MAPKAPK5OGATTKAKT1FYN | |
| SCHEMBL1674235 | 0.79 | MAPKAPK5 (0.65) | MAPKAPK5TTKSYKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885OGA 4662/4885TTK 4372/4885 |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885OGA 4662/4885TTK 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.